A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer

A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer

Abstract Background F-627 (efbemalenograstim alfa) is a novel long acting granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2) -Fc fragment with a peptide linker. This studyevaluated the efficacy and safety of F-627, also known as efb...

Full description

Bibliographic Details
Main Authors: Qingyuan Zhang, Zhonghua Wang, Wei Yao, Shufang Wang, Gaochong Zhang, Jianmin Chen, Qingsong Hou, Simon Li, Hongsheng Li, Changsheng Ye, Tao Sun, Hongjian Yang, Zhendong Chen, Zhihong Wang, Xiaoan Liu, Cuizhi Geng, Xingrui Li, Jin Zhang, Hong Zheng, Zhimin Shao
Format: Article
Language:English
Published: BMC 2024-09-01
Series:BMC Cancer
Subjects:
Breast cancer
Multicenter study
G-CSF
F-627
Efbemalenograstim alfa
Filgrastim
Online Access:https://doi.org/10.1186/s12885-024-12892-5

Internet

https://doi.org/10.1186/s12885-024-12892-5

Similar Items